Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
15 May 24
8-K
Changes in Registrant's Certifying Accountant
8 May 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Other Events
29 Mar 24
8-K
China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split
23 Feb 24
EFFECT
Notice of effectiveness
15 Feb 24
CORRESP
Correspondence with SEC
14 Feb 24
8-K
Entry into a Material Definitive Agreement
8 Feb 24
S-3/A
Shelf registration (amended)
6 Feb 24
CORRESP
Correspondence with SEC
6 Feb 24
UPLOAD
Letter from SEC
25 Jan 24
S-3
Shelf registration
12 Jan 24
8-K
Entry into a Material Definitive Agreement
21 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
19 Dec 23
UPLOAD
Letter from SEC
16 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
CORRESP
Correspondence with SEC
9 Nov 23
DEF 14A
Definitive proxy
7 Nov 23
PRE 14A
Preliminary proxy
27 Oct 23
UPLOAD
Letter from SEC
27 Oct 23
CORRESP
Correspondence with SEC
18 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Oct 23
UPLOAD
Letter from SEC
26 Sep 23
CORRESP
Correspondence with SEC
8 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
UPLOAD
Letter from SEC
25 Jul 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
Entry into a Material Definitive Agreement
20 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
Other Events
29 Mar 23
8-K
China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split
24 Feb 23
8-K
Submission of Matters to a Vote of Security Holders
30 Dec 22
8-K
Entry into a Material Definitive Agreement
2 Dec 22
8-K
China Pharma Announces Receipt of Noncompliance Notice from NYSE American
2 Dec 22
DEF 14A
Definitive proxy
14 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
PRE 14A
Preliminary proxy
4 Nov 22
S-8
Registration of securities for employees
24 Oct 22
8-K
China Pharma Announces Receipt of
30 Sep 22
10-Q
2022 Q2
Quarterly report
11 Aug 22